AcelRx Pharmaceuticals

AcelRx Pharmaceuticals FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of AcelRx Pharmaceuticals (ACRX) as of Oct 24, 2026 is 171.01 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -60.09 % — a change of -384.60% (higher).

FCF Conversion

171.01 %

YoY

-384.60%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of AcelRx Pharmaceuticals is 2023 171.01 % . FCF Conversion Rate (FCF/EBITDA) of AcelRx Pharmaceuticals was 2022 -60.09 % . It decreases by -384.60% higher compared to the previous year.

The AcelRx Pharmaceuticals FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2016
76.73 USD
Jan 1, 2017
62.46 USD
Jan 1, 2018
63.40 USD
Jan 1, 2019
102.65 USD
Jan 1, 2020
99.95 USD
Jan 1, 2021
90.68 USD
Jan 1, 2022
-60.09 USD
Jan 1, 2023
171.01 USD
The AcelRx Pharmaceuticals FCF Conversion history
YEARFCF ConversionYoY
171.01 %-384.60%
-60.09 %-166.26%
90.68 %-9.27%
99.95 %-2.63%
102.65 %+61.90%
63.40 %+1.52%
62.46 %-18.60%
76.73 %-12.55%
87.75 %-26.76%
119.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AcelRx Pharmaceuticals Stock analysis

What does AcelRx Pharmaceuticals do? AcelRx Pharmaceuticals Inc. is a California-based company specializing in the manufacturing of pain relief medications. The company was founded in 2005 and has since become an innovator in the development of pain medications. AcelRx's business model involves selling its patented products to hospitals and other healthcare facilities, and it is currently expanding into the global market. The company focuses on developing pain medications for emergency medicine and palliative care, with a particular emphasis on delivering medications through sprays or injections for fast-acting relief. AcelRx offers products such as Zalviso, a pain reliever based on Fentanyl nasal sprays used for post-operative pain, and Dsuvia, a sublingual tablet containing the active ingredient Sufentanil for severe pain. The FDA has approved Dsuvia as safe and effective. AcelRx has also entered partnerships with other pharmaceutical companies, such as Grünenthal and Chinese company R-Pharm, to bring its products to the international market. The company is committed to investing in research and development for innovative pain relief solutions, including a new research program targeting the development of medications for neuropathic pain. AcelRx Pharmaceuticals is a positive example of how modern pharmaceuticals can improve healthcare and quality of life. The company has demonstrated its potential through dedication and continuous research and development, and it is likely to make even greater contributions in the future. AcelRx Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AcelRx Pharmaceuticals stock

FCF Conversion Rate (FCF/EBITDA) of AcelRx Pharmaceuticals is 171.01 % in 2023.

FCF Conversion Rate (FCF/EBITDA) of AcelRx Pharmaceuticals changed from -60.09 % to 171.01 %, representing a -384.60% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) AcelRx Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s AcelRx Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — AcelRx Pharmaceuticals

All Key Metrics — AcelRx Pharmaceuticals